Compare ERC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | OBIO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.5M | 246.2M |
| IPO Year | N/A | 2020 |
| Metric | ERC | OBIO |
|---|---|---|
| Price | $8.85 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 73.4K | ★ 209.7K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $8.65 | $2.20 |
| 52 Week High | $9.78 | $5.42 |
| Indicator | ERC | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 59.02 |
| Support Level | N/A | $4.08 |
| Resistance Level | $9.47 | $4.88 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 9.47 | 82.43 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.